Abstract
The anti-allergic drug tranilast (TNL) reportedly exhibits inhibitory activity against epithelial-mesenchymal transition (EMT) at high concentrations. Herein, we synthesized a new hybrid molecule, tyrosine-conjugated TNL having a propyl linker (TNL-T), which is expected to increase anti-EMT activity by enhancing intracellular delivery through an amino acid transporter expressed in cancer cells. The anti-EMT activity of TNL-T was similar to that of TNL in the lung carcinoma cell line A549. Unlike TNL, TNL-T could induce dose-dependent cytotoxicity in A549 cells; this cytotoxicity was also observed in the glioblastoma cell lines U251 and U87. However, neither tyrosine nor TNL exhibited such cytotoxicity, demonstrating the importance of the TNL-T structure. The derivatization study showed that a derivative with an ethyl linker has the similar functions, and that of a pentyl linker was inactive. TNL-T, which exhibited dual activity by suppressing EMT and cancer cell proliferation, could aid in the development of new anticancer drugs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.